MARKET

CPRX

CPRX

Catalyst Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

4.430
+0.030
+0.68%
After Hours: 4.410 -0.02 -0.45% 17:45 05/27 EDT
OPEN
4.430
PREV CLOSE
4.400
HIGH
4.460
LOW
4.260
VOLUME
1.91M
TURNOVER
--
52 WEEK HIGH
7.67
52 WEEK LOW
2.550
MARKET CAP
458.12M
P/E (TTM)
10.99
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 6 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average CPRX stock price target is 8.25 with a high estimate of 10.00 and a low estimate of 6.50.

EPS

CPRX News

More
Catalyst Pharmaceuticals, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
Simply Wall St. · 05/14 13:18
Catalyst Pharmaceuticals Option Alert: Jun 19 $5 Calls Sweep (2) near the Ask: 861 @ $0.25 vs 3015 OI; Ref=$4.305
Benzinga · 05/13 17:25
SunTrust Robinson Humphrey Maintains Buy on Catalyst Pharmaceuticals, Lowers Price Target to $10
SunTrust Robinson Humphrey maintains Catalyst Pharmaceuticals (NASDAQ:CPRX) with a Buy and lowers the price target from $11 to $10.
Benzinga · 05/13 13:08
Catalyst Pharmaceuticals, Inc. (CPRX) CEO Patrick McEnany on Q1 2020 Results - Earnings Call Transcript
Seeking Alpha - Transcript · 05/12 16:42
GNFT, DT among premarket losers
Seeking Alpha - Article · 05/12 13:19
Catalyst Pharmaceuticals EPS beats by $0.01, misses on revenue
Catalyst Pharmaceuticals (NASDAQ:CPRX): Q1 Non-GAAP EPS of $0.12; GAAP EPS of $0.10 beats by $0.01. Revenue of $29.1M (+133.7% Y/Y) misses by $2.36M. Share
seekingalpha · 05/12 01:23
Catalyst Pharmaceutical (CPRX) Surpasses Q1 Earnings Estimates
Zacks · 05/12 00:25
Catalyst Pharmaceuticals Announces First Quarter 2020 Financial Results and Provides Corporate Update
GlobeNewswire · 05/11 21:17

Industry

Biotechnology & Medical Research
+0.53%
Pharmaceuticals & Medical Research
+0.23%

Hot Stocks

Symbol
Price
%Change

About CPRX

Catalyst Pharmaceuticals, Inc., formerly Catalyst Pharmaceutical Partners, Inc., is a development-stage biopharmaceutical company. The Company is focused on developing and commercializing therapies for people with rare debilitating diseases. The Company has three drugs in development: Firdapse, CPP-109 and CPP-115. The Company's Firdapse is indicated for the treatments of lambert-eaton myasthenic syndrome (LEMS) and congenital myasthenic syndromes (CMS). Firdapse consists of the phosphate salt of amifampridine. The Company has completed the Phase III trial of Firdapse. The Company's CPP-109 (vigabatrin) is a gamma-aminobutyric acid (GABA) aminotransferase inhibitor. CPP-109 is indicated for the treatment of Tourette's Disorder. The Company's CPP-115 is a GABA aminotransferase inhibitor. CPP-115 is indicated for the treatment of selected neurological indications, such as complex partial seizures and Tourette's Disorder, and epilepsy.
More

Webull offers kinds of Catalyst Pharmaceuticals Inc stock information, including NASDAQ:CPRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CPRX stock news, and many more online research tools to help you make informed decisions.